期刊
BRITISH JOURNAL OF CANCER
卷 100, 期 2, 页码 246-250出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6604838
关键词
pancreatic cancer; gemcitabine; 5-flurouracil; chemoradiation; randomized trial
类别
资金
- Cancer Research UK
- Fonds de Recherche de la Societe Nationale Francaise de Gastroenterologie
- Consorzio Studi Universitari di Verona, Cariverona and the Ministero Universita e Ricerca Scientifica e Tecnologica, Rome, Italy [Cofin 9906195987]
- Associazione Italiana Ricerca Cancro (AIRC) Milan, Italy
- European Community Grant [BMH4-CT98-3805]
- National Cancer Institute, Canada
- Medical Research Council, Australia
- MRC [G9900432] Funding Source: UKRI
- Medical Research Council [G9900432] Funding Source: researchfish
The ESPAC-1, ESPAC-1 plus, and early ESPAC-3(v1) results (458 randomized patients; 364 deaths) were used to estimate the effectiveness of adjuvant 5FU/FA vs resection alone for pancreatic cancer using meta-analysis. The pooled hazard ratio of 0.70 (95% CI = 0.55-0.88) P = 0.003, and the median survival of 23.2 (95% CI = 20.1-26.5) months with 5FU/FA vs 16.8 (95% CI = 14.3-19.2) months with resection alone supports the use of adjuvant 5FU/FA in pancreatic cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
